Last Updated on October 15, 2024 by The Health Master
Strides Pharma Science has announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte Singapore, has received approval for potassium chloride for oral solution USP, 20 mEq from the United States Food & Drug Administration (USFDA).
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), potassium chloride for oral solution USP, 20 mEq, of Pharma Research Software Solution, LLC.
Potassium chloride oral solution is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction are insufficient.
According to IQVIA MAT January 2021 data, the US market for potassium chloride for oral solution USP, 20 mEq is approximately US$ 56 million. The product will be manufactured at the company’s facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market.
The company has 127 cumulative ANDA filings with USFDA of which 100 ANDAs have been approved and 27 are pending approval.
Also read:
Pharma Companies recall these drugs in US
AstraZeneca gets DCGI approval for Osimertinib tablets
Lupin launches generic Nitazoxanide tablets
Dr Reddy’s gets 3 observations from USFDA for US-based API plant
World’s most expensive drug, costs ₹18 crore per dose
NATCO gets USFDA nod for Breast Cancer treatment drug
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
